Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the ...

Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

The story around Regeneron is shifting, and one big player just made it official.

Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?

Regeneron Pharmaceuticals has recently drawn renewed attention as investment funds, Wall Street analysts, and industry observers highlight its broad biologics pipeline, disciplined capital allocation, ...

Here’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple ...

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results. Several ...

The firm now models $4.35 billion in U.S. Eylea franchise revenues for 2026, well above the $3.86 billion consensus. BofA also highlighted upside from Dupixent, noting it “continues to deliver growth” ...

Regeneron (REGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 96.18 with a total volume of 127.00.

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.62% to $741.92 Thursday, on what proved to be an all-around favorable ...